Huntington Disease Clinical Trial
Official title:
Meaning Making Among Asymptomatic Individuals With a Positive Presymptomatic Genetic Test Result for Huntington Disease
This exploratory study will examine ways in which individuals approach a positive genetic
test for Huntington Disease (HD). HD is a neurodegenerative disorder that causes emotional,
cognitive, and movement problems, and currently there is no way to prevent, stop or reverse
the progression of the disease. It is passed down through a mutation in a normal gene, and
each child of an HD parent has a 50-50 chance of inheriting the HD gene. The study is
designed to explore how individuals adjust to their new genetic status and evaluate any
perceived mental or emotional barriers to that adjustment. Currently, little is known about
how individuals come to terms with a positive genetic test result for a condition that has no
known cure or effective treatment. The results of this study may give health care providers
and counselors more information about how to help patients who are at risk for developing HD
make sense of their new genetic status.
Candidates will be prescreened and referred to the study by clinics that specialize in
genetic testing and counseling. Candidates must be 18 years old or older and must have
received a positive genetic test result for HD at least one month prior to the study. They
must also perceive themselves to be asymptomatic-that is, without existing HD symptoms.
During the study, participants will be interviewed and asked a series of questions about
their decision to pursue testing, their life since the testing, and the things that they have
found helpful or unhelpful since receiving the test results. The interviews will be recorded
and will last approximately 60 minutes. Participants also will receive a follow-up phone call
within two to three days to ensure their general psychological well-being after the
interview.
Huntington Disease (HD) is a progressive neurological condition, eventually leading to death.
Presymptomatic, predictive genetic testing can inform individuals of their genetic status. A
positive genetic test result can be a threatening event. In adapting to threatening events
people often try and find meaning in the experience. Meaning making refers to the attempt to
understand an event or experience and its significance in the context of one's life. The
search for meaning can eventually lead to acceptance of an event or experience, and is
considered an important component of adaptation. Although it has been established that
testing for HD can be a significantly stressful event, and that meaning making is a frequent
response towards adaptation, little is known about this process among individuals faced with
a positive genetic test result for HD. This study will describe meaning making in a
population of presymptomatic individuals with a positive genetic test result for HD.
Semi-structured interviews will be conducted, recorded, transcribed, and analyzed. A typology
of common themes will be compiled and reported. Data gathered from these interviews will
improve understanding of the phenomenon of meaning making in this population, and will
contribute to the existing literature on the role of meaning making in cognitive adaptation.
This study will specifically help gain insight into the process of meaning making among
individuals who have tested positive for HD, and may potentially inform the ways in which
health care professionals can help facilitate meaning-making among this population, in their
process of adaptation to a stressful live event.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
Not yet recruiting |
NCT05360082 -
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
|
||
Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A |